{"disease":{"id":"disitamab-vedotin","name":"disitamab vedotin"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06185400","title":"RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":108,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT07159217","title":"Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":65,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}